Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
NCT06040086
Chronic Disease, Chronic Obstructive Pulmonary Disease (COPD)
Birmingham, Alabama, United States
View Trial DetailsNCT Number: NCT01627743
This is a multi-center, prospective, non-interventional study that aims to evaluate in daily clinical practice, the possible corelation between patIent perception of the ability to perform morning activities and physician evaluation; patients with COPD, grade C and D.
Looking for future studies?
Notify Me40 year and older
All sexes
Observational
Research Site, Bacau, Romania
CorRELation between PatIent PErception of the Ability to Perform Morning Activities and Findings on Clinical Examination in COPD Patients
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Baseline and 3 months
CDLM questionnaire is a simple self-reporting tool of the burden and ability of COPD patients to perform routine morning activities: washing, dressing, eating breakfast, walking around. For each of these morning activities the score is varying from 0 (indicating worst case) to 5 (indicating best case).
Time frame: Baseline and 3 months
General health status visual scale is assessing the physicians perception of the patient health status following the clinical examination. Based upon clinical evaluation, the physician will indicate the patient's general condition on a a scale consisting of 5 levels. The scale will be completed at each visit and the score can vary from 1(very bad general health status) to 5 (very good general health status) .
Time frame: Day 0 (visit1)
Demographic patient characteristics are:
Age (years), gender (male/female), weight (kg), height (cm), place of origin (urban, rural)
Time frame: up to 3 months
The physician will evaluate adherence to treatment, after discussion with patient, by completing a visual scale for evaluation patient's adherence to treatment (adherence will be assessed in percentage, by indicating at the scale the value from 0% to 100% adherence).
The visual scale has the following cut-off points: 0% (no adherence to treatment), 25% (poor adherence), 50% (medium adherence), 75% (good adherence), 100% (high adherence).
Time frame: up to 3 months
The pedometers register the total daily walking steps. Each morning, the subject will reset the device by pressing the on/reset button. At the end of the day, the patient will record the number of daily walking steps. The estimated value for number of walking steps is 2,500 - 4,500 steps/day (based on previous studies).
Time frame: up to 3 months
Exacerbation is defined as a worsening of COPD symptoms that is beyond day-to-day variations and that requires antibiotic treatment and/or short systemic corticoid treatment and/or emergency room visit with or without hospital admission (according to GOLD criteria and previous studies).
AstraZeneca
Industry
CorRELation Between PatIent PErception of the Ability to Perform Morning Activities and Findings on Clinical Examination in COPD Patients
Acronym: RELIEF
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06040086
Chronic Disease, Chronic Obstructive Pulmonary Disease (COPD)
Birmingham, Alabama, United States
View Trial DetailsNCT01917331
Chronic Disease, Chronic Obstructive Pulmonary Disease (COPD)
Szeged, Hungary
View Trial DetailsNCT06897748
Chronic Disease, Chronic Obstructive Pulmonary Disease (COPD)
Aramil, Russia
View Trial DetailsNCT04119934
Behavior, Chronic Disease
Toronto, Ontario, Canada
View Trial Details